门静脉插管化疗对结直肠癌肝转移的影响  

Portal Vein Catheterization Chemotherapy on The Impact of Colorectal Cancer Metastases in Liver

作　　者：何明刚 

机构地区：[1]彭州同一医院,彭州611930

出　　处：《中国医药导刊》2009年第2期184-185,共2页Chinese Journal of Medicinal Guide

摘　　要：目的:探讨门静脉插管化疗联合全身化疗与单纯全身化疗对预防结直肠癌肝转移的影响。方法:术中门静脉插管,术后立即行门静脉插管化疗,以5-FU1000mg加CF200rng加MMC12mg加NS1000ml从门静脉24小时持续滴人,连续3天。术后4周行全身化疗(5-FU 400～600mg/m^((2)) d_((1-5)),CF100mg d_((1-5)),DDP60～90mg/m^((2))d_((1)))。对照组以相同方案仅行全身化疗。结果:术后肝转移发生率治疗组和对照组分别为10.0%和43.8%,3年、5年生存率治疗组和对照组分别为70.0%、60.0%和56.3%、37.5%。结论:门静脉插管化疗联合全身化疗可以降低结直肠癌肝转移发生率。Objective：Explore the portal vein chemotherapy combined with systemic chemotherapy and systemic chemotherapy alone in preventing liver metastases of colorectal cancer. Methods： Poaal vein was eannulated in operation and immediate portal vein catheterization chemotherapy was performed after operation,5-FU lO00mg,CF 200mg and MMC 12mg in NS 1000ml from a 24-hour continuous intravenous rejection for 3 days. systemic chemotherapy was done after 4 weeksi 5-FU 400-600mg/m2 dt -5, CF 100 mg d1-5 - DDP 60 - 90mg/m2 d1 ）- The same program of systemic chemotherapy was given in control group. Results： The incidence of postoperative liver metastasis of treatment group and control group were 10.0% and 43.8% .3 year and 5 year survival rate of treatment group and control group were 70.0% ,60.0% and 56.3 % ,37.5 %. Condnsions ：Portal vein catheterization chemotherapy combined with systemic chemotherapy can reduce the incidence of colorectal cancer metastases in liver.

关 键 词：结直肠癌 门静脉 化疗 预防 肝转移 

分 类 号：R735.3[医药卫生—肿瘤]